MetrioPharm CEO Dr. Brysch as Panel Speaker at the European Life Science CEO Forum
- Dr. Wolfgang Brysch, CEO of MetrioPharm AG, is a speaker on the panel Autoimmune and Inflammatory Diseases on February 25th
Zurich, February 19, 2019. MetrioPharm AG, a pharmaceutical development company, announces that its CEO Dr. Wolfgang Brysch will participate in the 12th Annual European Life Science CEO Forum. This global life science industry forum will take place from February 25th to 26th in Zurich. It addresses the main challenges for 2019 in investment, partnering and alliance management. Key players contribute their insights in panels which cover the macro picture as well as innovation in the different therapeutic sectors. Dr. Brysch participates as a speaker on the panel Autoimmune and Inflammatory Diseases.
Dr. Wolfgang Brysch: "The pharma experts on the panel represent a variety of approaches and will be able to shed light on the topic of inflammation and autoimmune diseases from their respective perspectives. I look forward to an exciting exchange".
MetrioPharm AG is a pharmaceutical development company developing drugs for chronic inflammatory diseases such as psoriasis, arthritis, and multiple sclerosis. Such chronic diseases pose the greatest individual health risk. The goal of MetrioPharm AG is to make the therapy of chronic inflammatory diseases more effective and more tolerable. We hope to achieve a healthspan expansion for patients: We want to stop the progression of chronic inflammatory diseases as early as possible and significantly prolong the healthy lifespan of millions of people.
MetrioPharm AG was founded in 2007 and is headquartered in Zurich with research facilities in Berlin.
MP1032 is the lead compound of a class of proprietary immune modulators developed by MetrioPharm. MP1032 is believed to modulate the oxidative stress-mediated activation state of macrophages and downregulate the M1 state. In contrast to other immune-modulating and disease-modifying drugs, MP1032 does not impact T-cells and preferentially affects macrophages at the sites of inflammation. MP1032 has shown anti-inflammatory activity in animal models of disease and a favorable toxicology profile in pre-clinical studies.
For the first Phase II study with MP1032, the indication psoriasis was selected because this immune-induced inflammatory disease is regarded as a so-called »door-opener indication«. Successes in the treatment of psoriasis have already led to first indications of promise for use in other chronic inflammatory diseases, such as arthritis and multiple sclerosis.
This press release contains forward-looking statements that involve risks and uncertainties and are consistent with MetrioPharm's assessment as of the date of this release. Such forward-looking statements are neither promises nor guarantees, but are subject to numerous risks and uncertainties, many of which are beyond MetrioPharm's control, that could cause actual results to differ materially from those contemplated in these forward-looking statements. MetrioPharm does not assume any obligation to update forward-looking statements with respect to changed expectations or new events, conditions or circumstances on which these statements are based. A liability or guarantee and, if applicable, claims for topicality, correctness and completeness of these data and information are excluded and cannot be derived either explicitly or impliedly.
Head of Investor Relations & Corporate Communications
MetrioPharm Deutschland GmbH
Am Borsigturm 100
T +49 (0) 30 33 84 395 40
F +49 (0) 30 33 84 395 99